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Abstract
Isolated cerebral folate deficiency was detected in a 13-year-old girl with cognitive and motor
difficulties and juvenile rheumatoid arthritis. Her serum contains autoantibodies that block
membrane-bound folate receptors that are on the choroid plexus and diminish the uptake of folate
into the spinal fluid. Whereas her serum folate exceeded 21 ng/mL, her spinal fluid contained 3.2
ng/mL of 5-methyltetrahydrofolate as a consequence of the autoantibodies diminishing the uptake
of this folate.
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Case Report
A 13-year-old girl had neuropsychiatric disturbances, ataxia, and deterioration in cognitive
abilities. Juvenile rheumatoid arthritis was diagnosed at the age of 11 months with clinical
manifestations of bilateral knee and ankle swelling, intermittent fevers, and a macular rash.
She responded to naproxen; however, a systemic exacerbation at 5 years of age required
steroids and methotrexate. At 7 years of age, she complained of neck pain and unusual
visual phenomena characterized by colored spots with a firework pattern. Brain magnetic
resonance imaging (MRI) showed abnormal enhancement of the soft tissues surrounding the
odontoid process, and somatosensory-evoked potentials were abnormal upon left median
and posterior tibial nerve stimulation. She was diagnosed with C1–2 arthrosis syndrome1
(rheumatoid cervical myelopathy). Steroids and methotrexate were discontinued, and anti-
inflammatory therapy was initiated with injections of soluble tumor necrosis factor receptor
(etanercept) with symptomatic and neuroimaging resolution over several months. At 12
years of age, the patient was re-evaluated for significant behavioral problems characterized
by paranoid and suicidal ideations. She also complained of paresthesias in her extremities,
intermittent urinary incontinence, impaired writing skills, and deterioration of cognitive
abilities at school.
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Clinical Description
At 12 years of age, the patient was a cooperative girl in no distress and with normal speech.
General physical and cranial nerve examination was normal. Sensation was intact and
bilaterally active to fine touch, pinprick, and proprioception. Motor examination
demonstrated normal muscle bulk, tone, and strength. Bilateral fine tremors were apparent in
her arms and legs. Deep tendon reflexes were increased throughout; however, plantar
responses were flexor. Tandem gait and Romberg testing revealed unsteadiness. Bilateral
median and posterior tibial somatosensory-evoked potentials were normal. MRI scans of her
brain, craniocervical junction, and entire spinal cord were normal. Serum vitamin E and
vitamin B12 levels were normal. Serum folate was >21.7 ng/mL (reference, >5.4 ng/mL).
Cerebrospinal fluid contained 3.2 ng/mL of 5-methyltetrahydrofolate (reference range, 18–
55 ng/mL, Horizon Molecular Medicine Laboratory, Atlanta, Georgia). Other cerebrospinal
fluid studies, including lactate, neurotransmitter metabolites, neopterin, tetrahydrobiopterin,
myelin basic protein levels, routine biochemistry, and electrophoresis were all normal.
Serum contained folate receptor-1(FR-1) blocking autoantibodies against the plasma side of
the folate receptor of the choroid plexus. FR-1 blocking autoantibodies have been found to
prevent folate from binding to folate receptors on epithelial cells of the choroid plexus, thus
preventing entry of folate into the cerebrospinal fluid.2
Discussion
Our child presented with neurologic abnormalities at age 7 years with rheumatoid C1–2
arthrosis syndrome and cervical myelopathy with neck pain and abnormal neuroimaging.
She was successfully treated with conservative medical management (etanercept). Up to
70% of rheumatoid patients may develop cervical involvement within 10 years of disease
onset.1,3 Subsequently, at the age of 12 years, she developed ataxia and behavioral, and
cognitive changes. Rheumatoid cervical myelopathy was excluded by normal imaging of the
craniocervical junction. Previously, she was treated with methotrexate and etanercept;
however, she had not received methotrexate for many years. Prior methotrexate use raised
the possibility of folate deficiency as a cause of her symptoms. Methotrexate is a known
analogue of folic acid and serves to bind dihydrofolate reductase, effectively preventing the
systemic metabolism of folate.4 However, her systemic folate concentration was normal in
her serum. Etanercept had been useful in managing her cervical arthrosis and
rheumatological manifestations. Etanercept is a dimeric fusion protein of the type II tumor
necrosis factor receptor linked to the Fc portion of human IgG1.5 However, postmarketing
observations have occasionally documented inflammatory demyelination with paresthesias,
visual disturbances, confusion, gait disturbance, apraxia, facial palsy, and Guillain-Barré
syndrome.6,7 In our patient, these neurological complications seemed unlikely given her
normal brain and spine MRI and normal cerebrospinal fluid protein, myelin basic protein,
and IgG indices. However, a low concentration of 5-methyltetrahydrofolate was detected in
the cerebrospinal fluid with normal serum folate. This finding was confirmed by an elevated
autoantibody in the serum that binds to the choroids plexus and diminishes the uptake of
folate into the cerebrospinal fluid.
Idiopathic cerebral folate deficiency has been recognized in a cohort of children showing
normal development until the age of 4 months.8 At this age, these children began
demonstrating unrest, irritability, and sleep disturbances. Further development was
characterized by delayed acquisition of neurodevelopmental milestones, severe cognitive
delay, visual and hearing disturbances, progressive ataxia, dyskinesias, and ascending
paraparesis leading to spastic tetraplegia if untreated. An autoantibody to the FR-1 located
on the plasma side of the choroid plexus epithelium has been identified in these cases.2 The
function of the FR-1 receptor is to transport 5-methyltetrahydrofolate from the blood into the
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cerebrospinal fluid by means of receptor-mediated endocytosis. Impaired function of this
receptor results in normal to high serum folate level with a low cerebrospinal fluid folate
concentration. Although age at diagnosis varied, all identified patients have displayed a form
of cerebral folate deficiency with infantile onset. Cerebral folate deficiency was confirmed
in our adolescent patient by detection of autoantibodies in the serum against the folic acid
receptor.2 Furthermore, our patient is unusual in that she was developmentally normal and
symptom onset did not occur until late childhood. Our patient was started on folinic acid, a
reduced methyl-folate metabolite not requiring the FR-1 receptor for transport into the
cerebrospinal fluid. There was symptomatic neurological improvement beginning at 3
months after initiation of therapy. Two years later, while on folinic acid 45 mg daily, the
cerebrospinal fluid 5-methyltetrahydrofolate level was normal at 50 ng/mL (reference range,
18–55 ng/mL).
Patients with autoimmune disorders are known to produce a wide variety of autoantibodies.
Many of these autoantibodies appear unrelated to the pathogenesis of these disorders. We
are not aware of any screening that has previously been performed to detect FR-1
autoantibodies in patients with autoimmune disorders. Patients with rheumatoid arthritis are
known to produce antibodies to cartilage proteins and fibronectin, in addition to
antiphospholipid and antineutrophil cytoplasmic antibodies.9 It is possible that other
autoantibodies are produced and have yet to be elucidated, such as anti–FR-1
autoantibodies. Methotrexate with folate (or folinic acid) is frequently used in the
management of rheumatoid arthritis. In addition, autoantibodies can block the uptake of
folate through the choroid plexus into the central nervous system. It is therefore important
that folate receptor deficiency be considered in the differential diagnosis of neurological
symptoms in patients with rheumatoid arthritis.
Acknowledgments
Thanks to Dr Keith Hyland at Horizon Molecular Medical Laboratory, Atlanta, for cerebrospinal fluid
neurotransmitter and metabolite assays.
References
1. Kolen ER, Schmidt MH. Rheumatoid arthritis of the cervical spine. Semin Neurol. 2002; 22:179–
186. [PubMed: 12524563]
2. Ramaekers VT, Rothenberg SP, Sequeria JM, et al. Autoantibodies to folate receptors in the cerebral
folate deficiency syndrome. N Engl J Med. 2005; 352:1985–1991. [PubMed: 15888699]
3. Paimela L, Laasonen L, Kankaanpaa E, et al. Progression of cervical spine changes in patients with
early rheumatoid arthritis. J Rheumatol. 1997; 24:1280–1284. [PubMed: 9228125]
4. Endresen GKM, Husby G. Folate supplementation during methotrexate treatment of patients with
rheumatoid arthritis. Scand J Rheumatol. 2001; 30:129–134. [PubMed: 11469521]
5. Pearce GJ, Chikanza IC. Targeting tumour necrosis factor in the treatment of rheumatoid arthritis.
BioDrugs. 2001; 15:139–149. [PubMed: 11437680]
6. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor
therapy for inflammatory arthritides. Arthritis Rheum. 2001; 44:2862–2869. [PubMed: 11762947]
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis
factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N
Engl J Med. 1999; 240:253–259. [PubMed: 9920948]
8. Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol. 2004; 46:843–851.
[PubMed: 15581159]
9. Van Boekel MAM, Vossenaar ER, van den Hoogen FHJ. Autoantibody systems in rheumatoid
arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002; 4:87–93. [PubMed:
11879544]
Koenig et al. Page 3
J Child Neurol. Author manuscript; available in PMC 2011 April 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
